Assuming the worst may not be bad at all
| Autor: | Martin Wehling, Bernhard Schmidt, C. P. Janson |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Pharmacology
medicine.medical_specialty Ventricular function Heart disease business.industry General Medicine medicine.disease Clinical trial Collaborative group Heart failure Internal medicine Anesthesia Large study Cardiology Medicine Pharmacology (medical) business Standard therapy Carvedilol medicine.drug |
| Zdroj: | European Journal of Clinical Pharmacology. 54:281-285 |
| ISSN: | 1432-1041 0031-6970 |
| DOI: | 10.1007/s002280050460 |
| Popis: | Objective: Carvedilol, a β-adrenoceptor blocking agent with additional α1-adrenoceptor blocking properties, has been shown to improve left ventricular function in chronic heart failure (CHF). However, its effect on mortality has recently been the subject of controversial discussion. The aim of this meta-analysis is to review the data on mortality from two large study programs (the US Carvedilol Heart Failure Study and the study by the Australia/New Zealand Heart Failure Research Collaborative Group) on additional carvedilol treatment in CHF standard therapy and to analyse the design and limitations of the individual studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink